Johnson & Johnson (JNJ) Enterprise Value (2009 - 2026)
Johnson & Johnson (JNJ) posted Enterprise Value of -$22.1 billion for Q1 2026, down 9.7% sequentially from -$20.1 billion in Q4 2025, and up 43.14% YoY from -$15.4 billion in Q1 2025.
Johnson & Johnson (JNJ) Enterprise Value (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Enterprise Value data on file, last reported at -$22.1 billion in Q1 2026.
- Quarterly Enterprise Value rose 43.14% year-over-year to -$22.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$22.1 billion (up 43.14% YoY) and the FY2025 annual result came in at -$20.1 billion, up 18.02% from the prior year.
- Enterprise Value retreated to -$22.1 billion in Q1 2026 per JNJ's latest filing, from -$20.1 billion in the prior quarter.
- The five-year high for Enterprise Value was -$18.6 billion in Q3 2025, with the low at -$38.8 billion in Q1 2025.
- Average Enterprise Value over 5 years is -$25.8 billion, with a median of -$24.6 billion recorded in 2023.
- Year-over-year, Enterprise Value sank 47.92% in 2025 and surged 43.14% in 2026.
- Johnson & Johnson's Enterprise Value stood at -$34.1 billion in 2022, then soared by 32.72% to -$22.9 billion in 2023, then fell by 6.96% to -$24.5 billion in 2024, then increased by 18.02% to -$20.1 billion in 2025, then retreated by 9.7% to -$22.1 billion in 2026.
- Business Quant data shows JNJ's Enterprise Value at -$22.1 billion in Q1 2026, -$20.1 billion in Q4 2025, and -$18.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -5.28 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -22.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -9.35 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -7.89 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 315.00 Mn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | -4.28 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | -22.05 Bn |
| Dec 28, 2025 | -20.10 Bn |
| Sep 28, 2025 | -18.56 Bn |
| Jun 29, 2025 | -18.88 Bn |
| Mar 30, 2025 | -38.78 Bn |
| Dec 29, 2024 | -24.52 Bn |
| Sep 29, 2024 | -20.30 Bn |
| Jun 30, 2024 | -25.48 Bn |
| Mar 31, 2024 | -26.22 Bn |
| Dec 31, 2023 | -22.93 Bn |
| Oct 1, 2023 | -23.51 Bn |
| Jul 2, 2023 | -27.25 Bn |
| Apr 2, 2023 | -24.61 Bn |
| Jan 1, 2023 | -22.28 Bn |
| Oct 2, 2022 | -34.08 Bn |
| Jul 3, 2022 | -32.57 Bn |
| Apr 3, 2022 | -30.39 Bn |
| Jan 2, 2022 | -31.61 Bn |
| Oct 3, 2021 | -31.00 Bn |
| Jul 4, 2021 | -25.31 Bn |